Iovance Biotherapeutics Inc (NAS:IOVA)
$ 7.78 -0.36 (-4.42%) Market Cap: 2.18 Bil Enterprise Value: 2.01 Bil PE Ratio: 0 PB Ratio: 3.20 GF Score: 35/100

Iovance Biotherapeutics Inc at Credit Suisse Healthcare Conference - Scottsdale Transcript

Nov 12, 2019 / 11:45PM GMT
Release Date Price: $22.9 (-4.06%)
Evan David Seigerman;dit Suisse AG
CrÃ;Research Division - VP & Senior Equity Research Analyst

© -

Hi, there. My name is Evan Seigerman. I am the senior large-cap biotechnology analyst here at Crédit Suisse. And it is my pleasure to introduce Iovance Therapeutics. And from Iovance is the CFO, Tim Morris.

Timothy E. Morris
Iovance Biotherapeutics, Inc. - CFO, Principal Accounting Officer, Corporate Secretary & Treasurer

Thank you very much. Thank you, Evan, for that kind introduction. Thank you again to Crédit Suisse. It's always a pleasure to come down to Scottsdale and present to the audience and those out here on the webcast. Again, I'm Tim Morris, Chief Financial Officer.

I will make forward-looking statements during the course of this presentation. So please refer to my SEC documents for information and risk that will impact your investment decision.

A little bit of a time line here. It is kind of amazing how much the company has been able to accomplish in at about 3 years. The technology was

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot